Sanofi-Aventis Considers Taxotere Name Change To Avoid Misuse In Japan
This article was originally published in PharmAsia News
Executive Summary
Sanofi-Aventis is considering a name change for cancer drug Taxotere (docetaxel) in Japan, according to officials at Japan's Ministry of Health, Labor and Welfare